We are live on ! Find out more
SYRS

Syros Pharmaceuticals, Inc. Common Stock
SYRS

Delisted

SYRS was delisted on the 19th of March, 2025.

Back to rankings

12 hedge funds and large institutions have $207M invested in Syros Pharmaceuticals, Inc. Common Stock in 2016 Q2 according to their latest regulatory filings, with 12 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
12
Holders Change
+12
Holders Change %
–
% of All Funds
0.32%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
12
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$54.9M
2
DM
Deerfield Management
New York
+$38M
3
RG
Redmile Group
California
+$17.2M
4
AC
Aisling Capital
New York
+$16.5M
5
BBA
Baker Bros. Advisors
New York
+$3.71M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
FVFIGP
1
Flagship Ventures Fund IV General Partner
Massachusetts
$87.2M +$87.2M +480,666 New
DM
2
Deerfield Management
New York
$38M +$38M +209,522 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$37.8M +$54.9M +302,729 New
AC
4
Aisling Capital
New York
$16.5M +$16.5M +90,857 New
RG
5
Redmile Group
California
$15.1M +$17.2M +94,618 New
BBA
6
Baker Bros. Advisors
New York
$3.71M +$3.71M +20,447 New
EAM
7
Eventide Asset Management
Massachusetts
$2.72M +$2.72M +15,000 New
FCMI
8
Foresite Capital Management III
California
$2.72M +$2.72M +15,000 New
Alyeska Investment Group
9
Alyeska Investment Group
Illinois
$1.27M +$1.27M +7,000 New
CC
10
Casdin Capital
New York
$908K +$908K +5,000 New
WMSA
11
Weiss Multi-Strategy Advisers
New York
$832K +$832K +4,586 New
Goldman Sachs
12
Goldman Sachs
New York
$363K +$363K +2,000 New

SYRS Hedge Fund Activity: Q2 2016 in Review

12 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q2 2016, worth a combined $207M.

Buyers outnumbered sellers: 12 funds opened new SYRS positions and 0 closed out — a net gain of 12 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, opening a new position worth an estimated $54.9M.

  • 12 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q2 2016, up from 0 in Q1 2016.
  • Funds reported $207M of Syros Pharmaceuticals, Inc. Common Stock stock for Q2 2016.
  • 12 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q2 2016 and 0 closed out, a net change of +12 holders.
  • The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q2 2016 was Fidelity Investments, an estimated $54.9M added.

Based on aggregated 13F filings for Q2 2016.